# Cefotetan Therapy for Escherichia Coli Infections

> **NCT07318584** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Oregon Health and Science University** · enrollment: 84 (estimated)

## Conditions studied

- E Coli Infection
- ESBL Producing E.Coli

## Interventions

- **DRUG:** Cefotetan
- **DRUG:** Carbapenems
- **DRUG:** Beta Lactam Antibiotics

## Key facts

- **NCT ID:** NCT07318584
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-02
- **Final completion:** 2028-08
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318584, "Cefotetan Therapy for Escherichia Coli Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07318584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*